Application Detail
Status
ClosedDescription of Medical Service
ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.Description of Medical Condition
ALK-positive advanced NSCLC.Reason for Application
-Medical Service Type
-Previous Application Number
1250Associated Documentation
Application Form
-PICO Confirmation
Final Protocol (PDF 585 KB)Final Protocol (Word 6128 KB)
Assessment Report
-Public Summary Document
Public Summary Document - November 2014 Update (PDF 273 KB)Public Summary Document - November 2014 Update (Word 111 KB)
Meetings for this Application
PASC
-ESC
12 to 13 June 2014MSAC
3 October 201426 to 28 November 2014